Literature DB >> 25072696

NEDD4 ubiquitinates TRAF3 to promote CD40-mediated AKT activation.

Di-Feng Fang1, Kun He1, Na Wang1, Zhi-Hong Sang2, Xin Qiu2, Guang Xu2, Zhao Jian2, Bing Liang2, Tao Li2, Hui-Yan Li2, Ai-Ling Li2, Tao Zhou2, Wei-Li Gong2, Baoli Yang3, Michael Karin4, Xue-Min Zhang2, Wei-Hua Li2.   

Abstract

CD40, a member of tumour necrosis factor receptor (TNFR) superfamily, has a pivotal role in B-cell-mediated immunity through various effector pathways including AKT kinase, but the signal transduction of CD40-meidated AKT activation is poorly understood. Here we report that the neural precursor cell expressed developmentally downregulated protein 4 (NEDD4), homologous to E6-AP Carboxyl Terminus family E3 ubiquitin ligase, is a novel component of the CD40 signalling complex. It has a key role in CD40-mediated AKT activation and is involved in modulating immunoglobulin class switch through regulating the expression of activation-induced cytidine deaminase. NEDD4 constitutively interacts with CD40 and mediates K63-linked ubiquitination of TNFR-associated factor3 (TRAF3). The ubiquitination of TRAF3 by NEDD4 is critical for CD40-mediated AKT activation. Thus, NEDD4 is a previously unknown component of the CD40 signalling complex necessary for AKT activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25072696     DOI: 10.1038/ncomms5513

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  18 in total

1.  The kinase CK1ɛ controls the antiviral immune response by phosphorylating the signaling adaptor TRAF3.

Authors:  Yilong Zhou; Chenxi He; Dapeng Yan; Feng Liu; Haipeng Liu; Jianxia Chen; Ting Cao; Mianyong Zuo; Peng Wang; Yan Ge; Haojie Lu; Qinghe Tong; Chengfeng Qin; Yongqiang Deng; Baoxue Ge
Journal:  Nat Immunol       Date:  2016-02-29       Impact factor: 25.606

2.  E3 ubiquitin ligase Nedd4 is a key negative regulator for non-canonical inflammasome activation.

Authors:  Qingjun Liu; Shihui Zhang; Zhongjie Sun; Xiao Guo; Hong Zhou
Journal:  Cell Death Differ       Date:  2019-02-28       Impact factor: 15.828

3.  HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection.

Authors:  Fubing Li; Yang Li; Huichun Liang; Tao Xu; Yanjie Kong; Maobo Huang; Ji Xiao; Xi Chen; Houjun Xia; Yingying Wu; Zhongmei Zhou; Xiaomin Guo; Chunmiao Hu; Chuanyu Yang; Xu Cheng; Ceshi Chen; Xiaopeng Qi
Journal:  J Clin Invest       Date:  2018-07-30       Impact factor: 14.808

Review 4.  NEDD4: The founding member of a family of ubiquitin-protein ligases.

Authors:  Natasha Anne Boase; Sharad Kumar
Journal:  Gene       Date:  2014-12-17       Impact factor: 3.688

Review 5.  TRAF3, ubiquitination, and B-lymphocyte regulation.

Authors:  Wai W Lin; Bruce S Hostager; Gail A Bishop
Journal:  Immunol Rev       Date:  2015-07       Impact factor: 12.988

6.  Activation of cell-surface proteases promotes necroptosis, inflammation and cell migration.

Authors:  Zhenyu Cai; Anling Zhang; Swati Choksi; Weihua Li; Tao Li; Xue-Min Zhang; Zheng-Gang Liu
Journal:  Cell Res       Date:  2016-07-22       Impact factor: 25.617

7.  TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-κB1 Activation.

Authors:  Rachel A Woolaver; Xiaoguang Wang; Yonatan Dollin; Ping Xie; Jing H Wang; Zhangguo Chen
Journal:  J Immunol       Date:  2018-10-19       Impact factor: 5.422

Review 8.  TRAF3 as a powerful and multitalented regulator of lymphocyte functions.

Authors:  Gail A Bishop
Journal:  J Leukoc Biol       Date:  2016-05-06       Impact factor: 4.962

9.  NEDD4 regulates ubiquitination and stability of the cell adhesion molecule IGPR-1 via lysosomal pathway.

Authors:  Linzi Sun; Razie Amraei; Nader Rahimi
Journal:  J Biomed Sci       Date:  2021-05-07       Impact factor: 8.410

Review 10.  Regulation of the Tumor-Suppressor Function of the Class III Phosphatidylinositol 3-Kinase Complex by Ubiquitin and SUMO.

Authors:  Christina Reidick; Fouzi El Magraoui; Helmut E Meyer; Harald Stenmark; Harald W Platta
Journal:  Cancers (Basel)       Date:  2014-12-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.